Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Imigran 20 mg Nasal Spray, Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each nasal applicator contains 20 mg of sumatriptan in 0.1 ml of solution. For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Nasal spray, solution.

Product imported from France:
A clear, pale to dark yellow, buffered solution.

4 CLINICAL PARTICULARS

As per PA1077/008/004

5 PHARMACOLOGICAL PROPERTIES

As per PA1077/008/004

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Potassium dihydrogen phosphate Disodium phosphate anhydrous Sulphuric acid Sodium hydroxide Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin.

6.4 Special precautions for storage

Do not store above 30°C. Store in the original package in order to protect from light. Do not freeze.

6.5 Nature and contents of container

Imigran Nasal Spray is supplied in ampoule. Each unit dose spray device containing 0.1 ml solution is presented in an individually sealed blister.

Packs contain 6 sprays.

18 July 2023 CRN00DL02 Page 1 of 2

Health Products Regulatory Authority

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd, Unit 625 Kilshane Avenue, Northwest Business Park, Ballycoolin, Dublin 15, Ireland.

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1463/211/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17th July 2023

10 DATE OF REVISION OF THE TEXT

18 July 2023 CRN00DL02 Page 2 of 2